LANDSVIRKJUN
14.12.2016 12:02:27 CET | Business Wire | Press release
Landsvirkjun, the National Power Company of Iceland, and Advania have signed a power purchase agreement for the supply of energy to Advania’s Fitjar data centre in the southwest of Iceland. The energy will be supplied by the end of 2016 according to the agreement, which will enable Advania to continue to expand their data center operations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161214005221/en/
Landsvirkjun will supply the energy through its current power station network. The company has supported the growth of the data center industry in recent years in Iceland by offering energy from 100% renewable resources.
Hörður Arnarson, CEO of Landsvirkjun:
"Advania is a welcome addition to Landsvirkjun’s client base. The conditions in Iceland are ideal for data center operations and Landsvirkjun has in recent years actively promoted Iceland as a preferred location for data centers. The successful growth of Advania and other data centers in Iceland is based on favourable, long-term, secure energy contracts, a competitive environment and the cooperation of stakeholders within the industry in Iceland."
Gestur G. Gestsson, CEO of Advania:
"The scope of Advania’s operations, within the data center market, has grown tremendously in recent years and large-scale projects are in the pipeline in the coming months. Access to energy is a key factor in the operation of data centers and we are therefore greatly pleased by this agreement with Landsvirkjun. We believe That Landsvirkjun will strengthen our ability to service more global clients in the future. "
Advania is a leading Nordic IT company with operations in Iceland, Sweden and Norway. The company has around 1000 employees, working from 20 different stations of operation. Advania operates the Steinhella Data Center in Hafnarfjordur and the Fitjar Data Center in Reykjanesbær. The agreement will allow the company to further grow its data center operations and add to its client base.
Landsvirkjun generates 100% of its power from renewable resources. The company owns and operates 16 power stations, including 14 hydropower stations and two geothermal stations as well as two wind turbines. Landsvirkjun is currently constructing a geothermal power station at Þeistareykir in the northeast of Iceland and is also expanding its hydropower station network in Búrfell, in the south of Iceland.
The offering of favourable long-term power purchase agreements makes Iceland a competitive location to set up data centers and the stable, cold climate of the country is particularly suitable for data center operations. Redundant submarine fibre cable system provides the reliable connectivity required by demanding international data centers.
Landsvirkjun has actively promoted Iceland to the responsible parties for determining future locations of data centers. The Company's website contains information on the benefits of Iceland in this regard:
http://www.landsvirkjun.com/datacenters
View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005221/en/
Contact:
Landsvirkjun
Magnús Þór Gylfason, +354 515 9000
Director of
Corporate Communications
Magnus.Thor.Gylfason@landsvirkjun.is
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
